DƯỢC LÍ Goodman & Gilman's The Pharmacological Basis of Therapeutics 12th, 2010

Murphy R, Ellard S, Hattersley AT. Clinical implications of a
molecular genetic classification of monogenic beta-cell diabetes.
Nat Clin Pract Endocrinol Metab, 2008, 4:200–213.
Nathan DM, Buse JB, Davidson MB, et al. Medical management
of hyperglycemia in type 2 diabetes: A consensus algorithm
for the initiation and adjustment of therapy; a consensus statement
of the American Diabetes Association and the European
Association for the Study of Diabetes. Diabetes Care, 2009,
32:193–203.
Nesto RW, Bell D, Bonow RO, et al. Thiazolidinedione use,
fluid retention, and congestive heart failure: A consensus
statement from the American Heart Association and American
Diabetes Association. Circulation, 2003, 108: 2941–2948.
Pocock SJ, Smeeth L. Insulin glargine and malignancy: an
unwarranted alarm. Lancet, 2009, 374:511–513.
Rosen CJ, Revisiting the Rosiglitazone story—Lessons Learned.
N Engl J Med, 2010, 363:803-806.
Rosenstock J, Hassman DR, Madder RD, et al. Repaglinide versus
nateglinide monotherapy. Diabetes Care, 2004,
27:1265–1270.
Ryan EH Jr, Han DP, Ramsay RC, et al. Diabetic macular edema
associated with glitazone use. Retina, 2006, 26:562–570.
Savage DB, Petersen KF, Shulman GI. Disordered lipid metabolism
and the pathogenesis of insulin resistance. Physiol Rev,
2007, 87:507–520.
Scarpello JH, Howlett HC. Metformin therapy and clinical uses.
Diab Vasc Dis Res, 2008, 5:157–167.
Shaw RJ, Lamia KA, Vasquez D, et al. The kinase LKB1 mediates
glucose homeostasis in liver and therapeutic effects of
metformin. Science, 2005, 310:1642–1646.
Sjostrom L, Lindroos A-K, Peltonen M, et al. Lifestyle, diabetes,
and cardiovascular risk factors 10 years after bariatric surgery.
N Engl J Med, 2004, 351:2683–2693.
JS Skyler, Therapy for Diabetes Mellitus and Related Disorders.,
Alexandria, VA: American Diabetes Association, 2004.
Skyler JS, Bergenstal R, Bonow RO, et al. Intensive glycemic
control and the prevention of cardiovascular events:
Implications of the ACCORD, ADVANCE, and VA Diabetes
Trials; a position statement of the American Diabetes
Association and a Scientific Statement of the American
College of Cardiology Foundation and the American Heart
Association. J Am Coll Cardiol, 2009, 53:298–304.
Smith U, Gale EA. Does diabetes therapy influence the risk of
cancer? Diabetologia, 2009, 52:1699–1708.
Sonnett TE, Levien TL, Neumiller, JJ, et al. Colesevelam
hydrochloride for the treatment of type 2 diabetes mellitus.
Clin Ther, 2009, 31:245–259.
Taniguchi CM, Emanuelli B, Kahn CR. Critical nodes in signalling
pathways: insights into insulin action. Nat Rev Mol
Cell Biol, 2006, 7:85–96.
Taylor R. Pathogenesis of type 2 diabetes: Tracing the reverse
route from cure to cause. Diabetologia, 2008, 51:1781–1789.
van den Berghe G, Wouters P, Weekers F, et al. Intensive insulin
therapy in the critically ill patients. N Engl J Med, 2001,
345:1359–1367.
Vaxillaire M, Froguel P. Monogenic diabetes in the young, pharmacogenetics
and relevance to multifactorial forms of type 2
diabetes. Endocr Rev, 2008, 29:254–264.
von Herrath M, Sanda S, Herold K. Type 1 diabetes as a relapsing-remitting
disease? Nat Rev Immunol, 2007, 7:988–994.
Weinstein D, Simon M, Yehezkel E, et al. Insulin analogues display
IGF-I-like mitogenic and anti-apoptotic activities in cultured
cancer cells. Diabetes Metab Res Rev, 2009, 25:41–49.
Weithop BV, Cryer PE. Glycemic actions of alanine and terbutaline
in IDDM. Diabetes Care, 1993, 16:1124–1130.
Weng J, Li Y, Xu W, et al. Effect of intensive insulin therapy on
beta-cell function and glycaemic control in patients with newly
diagnosed type 2 diabetes: A multicentre randomised parallelgroup
trial. Lancet, 2008, 371:1753–1760.
Yki-Jarvinen H. Thiazolidinediones. N Engl J Med, 2004,
351:1106–1118.
Zaid H, Antonescu CN, Randhawa VK, Klip A. Insulin action
on glucose transporters through molecular switches, tracks and
tethers. Biochem J, 2008, 413:201–215.
Zhou G, Myers R, Li Y, et al. Role of AMP-activated protein
kinase in mechanism of metformin action. J Clin Invest, 2001,
108:1167–1174.
1273
CHAPTER 43
ENDOCRINE PANCREAS AND PHARMACOTHERAPY OF DIABETES MELLITUS AND HYPOGLYCEMIA